Syntonia Sp. z o.o.

The trials here

What the 2 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease1 trial
• Depression1 trial

Phase

• Phase 21 trial
• Phase 31 trial

Status

• Completed2 trials

Lead sponsor

• HMNC Holding GmbH1 trial
• Otsuka Pharmaceutical Development & Commercialization Inc.1 trial

Closed trials

• Completed

  A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) in outpatients with Major Depressive Disorder (MDD)

  2024-513104-34-00· Phase 2· HMNC Holding GmbH· Source

• Completed

  Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

  NCT04408755· Phase 3· Otsuka Pharmaceutical Development & Commercialization Inc.· Source